Ruelle-Perron-Frobenius spectrum for Anosov maps

We extend a number of results from one dimensional dynamics based on spectral properties of the Ruelle-Perron-Frobenius transfer operator to Anosov diffeomorphisms on compact manifolds. This allows to develop a direct operator approach to study ergodic properties of these maps. In particular, we show that it is possible to define Banach spaces on which the transfer operator is quasicompact. (Information on the existence of an SRB measure, its smoothness properties and statistical properties readily follow from such a result.) In dimension $d=2$ we show that the transfer operator associated to smooth random perturbations of the map is close, in a proper sense, to the unperturbed transfer operator. This allows to obtain easily very strong spectral stability results, which in turn imply spectral stability results for smooth deterministic perturbations as well. Finally, we are able to implement an Ulam type finite rank approximation scheme thus reducing the study of the spectral properties of the transfer operator to a finite dimensional problem.Comment: 58 pages, LaTe

Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors

Introduction Biomarkers indicating trait, progression and prediction of pathology and symptoms in Parkinson's disease (PD) often lack specificity or reliability. Investigating biomarker variance between individuals and over time and the effect of confounding factors is essential for the evaluation of biomarkers in PD, such as insulin-like growth factor 1 (IGF-1). Materials and Methods IGF-1 serum levels were investigated in up to 8 biannual visits in 37 PD patients and 22 healthy controls (HC) in the longitudinal MODEP study. IGF-1 baseline levels and annual changes in IGF-1 were compared between PD patients and HC while accounting for baseline disease duration (19 early stage: 3.5 years; 18 moderate stage: >4 years), age, sex, body mass index (BMI) and common medical factors putatively modulating IGF-1. In addition, associations of baseline IGF-1 with annual changes of motor, cognitive and depressive symptoms and medication dose were investigated. Results PD patients in moderate (130±26 ng/mL; p = .004), but not early stages (115±19, p>.1), showed significantly increased baseline IGF-1 levels compared with HC (106±24 ng/mL; p = .017). Age had a significant negative correlation with IGF-1 levels in HC (r = -.47, p = .028) and no correlation in PD patients (r = -.06, p>.1). BMI was negatively correlated in the overall group (r = -.28, p = .034). The annual changes in IGF-1 did not differ significantly between groups and were not correlated with disease duration. Baseline IGF-1 levels were not associated with annual changes of clinical parameters. Discussion Elevated IGF-1 in serum might differentiate between patients in moderate PD stages and HC. However, the value of serum IGF-1 as a trait-, progression- and prediction marker in PD is limited as IGF-1 showed large inter- and intraindividual variability and may be modulated by several confounders

The CMS Phase-1 pixel detector upgrade

The CMS detector at the CERN LHC features a silicon pixel detector as its innermost subdetector. The original CMS pixel detector has been replaced with an upgraded pixel system (CMS Phase-1 pixel detector) in the extended year-end technical stop of the LHC in 2016/2017. The upgraded CMS pixel detector is designed to cope with the higher instantaneous luminosities that have been achieved by the LHC after the upgrades to the accelerator during the first long shutdown in 2013–2014. Compared to the original pixel detector, the upgraded detector has a better tracking performance and lower mass with four barrel layers and three endcap disks on each side to provide hit coverage up to an absolute value of pseudorapidity of 2.5. This paper describes the design and construction of the CMS Phase-1 pixel detector as well as its performance from commissioning to early operation in collision data-taking.Peer reviewe

TOWARDS AN ONTOLOGY-BASED CUSTOMIZATION APPROACH FOR SUPPORTING PEOPLE WITH SPECIAL NEEDS

People with disabilities encounter serious limitations in interacting with their home environment since their requirements are not met properly. Personal assisting devices interacting with the services offered by smart home environments can help to improve the quality of their lives. A major prerequisite for this is to provide an appropriate customization architecture which allows to reason about the person’s current situation in terms of personal, technical and natural context and to adapt the home environment’s services accordingly. This paper proposes a customization approach based on an ontology which comprehensively represents the situation of persons with special needs for the purpose of adapting their home environment’s services. 1

AsTeRICS, a Flexible Assistive Technology Construction Set

AbstractOver the last decades a considerable number of information and communication technology based Assistive Technology devices have become available for people with disabilities. These Assistive Technology devices often ask for adaptation of software and/or hardware to fit the users abilities before they can be used.Within the Project AsTeRICS, a flexible and affordable construction set for the implementation of user driven assistive technologies solutions will be developed. This allows the combination of different sensors to process and manipulate the sensor data to control any supported device. This paper will show how a webcam mouse (head tracker) and a single switch mouse can easily be created and tailored to the user needs and possibilities. Additionally, results of user tests with the head tracker will be presented

Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524

Abstract The kinase Bub1 functions in the spindle assembly checkpoint (SAC) and in chromosome congression, but the role of its catalytic activity remains controversial. Here, we use two novel Bub1 inhibitors, BAY-320 and BAY-524, to demonstrate potent Bub1 kinase inhibition both in vitro and in intact cells. Then, we compared the cellular phenotypes of Bub1 kinase inhibition in HeLa and RPE1 cells with those of protein depletion, indicative of catalytic or scaffolding functions, respectively. Bub1 inhibition affected chromosome association of Shugoshin and the chromosomal passenger complex (CPC), without abolishing global Aurora B function. Consequently, inhibition of Bub1 kinase impaired chromosome arm resolution but exerted only minor effects on mitotic progression or SAC function. Importantly, BAY-320 and BAY-524 treatment sensitized cells to low doses of Paclitaxel, impairing both chromosome segregation and cell proliferation. These findings are relevant to our understanding of Bub1 kinase function and the prospects of targeting Bub1 for therapeutic applications

IGF-1 as a predictor of changes in clinical parameters.

<p>PD patient groups with low and high IGF-1 baseline levels (median split at 122 ng/mL). Groups show no significant differences (p > .1) in annual changes of (a) PD-motor symptom severity (UPDRS-III), (b) PD-medication (L-dopa equivalent dose, LED), (c) depressive symptoms (BDI score) and (d) global cognitive function (MMSE score).</p